Review




Structured Review

ImmunoGen Inc cellular immunogen
Cellular Immunogen, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular+immunogen/t+cell+immunogen/us12018078-388-36-31
Average 90 stars, based on 1 article reviews
cellular immunogen - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

Sequencing:

Article Title: SEMA4D antibody, preparation method therefor and use thereof
Article Snippet: C. DNA Immunogen: The nucleotide sequence containing the sequence encoding the full length of human SEMA4D (as shown in SEQ ID No: 422 in sequence listing, as shown in the cellular immunogen) was cloned into the pCP vector, and the plasmid pCP-hSEMA4D was prepared according to the above method. (II) Preparation of Hybridoma Cells and Screening of Antibody A.

Article Title: TRAIL Deficiency Does Not Rescue Impaired CD8 + T Cell Memory Generated in the Absence of CD4 + T Cell Help
Article Snippet: Using a cellular immunogen requiring cross-priming or lymphocytic choriomeningitis virus (LCMV) infection, it was demonstrated that mRNA for TRAIL was selectively up-regulated in unhelped CD8 + T cells following in vitro restimulation and that TRAIL blockade rescued the expansion of restimulated CD8 + T cells ( 13 ).

Article Title: Compositions and methods for tumour therapy
Article Snippet: One method of using the vectors, provided by this invention, is to prepare a cellular immunogen such as a vaccine from tumour cells derived from one or more individuals by treating such tumour cells with a vector for downregulating osteonectin, and to administer this as an immunogen or vaccine for treatment of other subjects, e.g. patients.

Clone Assay:

Article Title: SEMA4D antibody, preparation method therefor and use thereof
Article Snippet: C. DNA Immunogen: The nucleotide sequence containing the sequence encoding the full length of human SEMA4D (as shown in SEQ ID No: 422 in sequence listing, as shown in the cellular immunogen) was cloned into the pCP vector, and the plasmid pCP-hSEMA4D was prepared according to the above method. (II) Preparation of Hybridoma Cells and Screening of Antibody A.

Article Title: TRAIL Deficiency Does Not Rescue Impaired CD8 + T Cell Memory Generated in the Absence of CD4 + T Cell Help
Article Snippet: Using a cellular immunogen requiring cross-priming or lymphocytic choriomeningitis virus (LCMV) infection, it was demonstrated that mRNA for TRAIL was selectively up-regulated in unhelped CD8 + T cells following in vitro restimulation and that TRAIL blockade rescued the expansion of restimulated CD8 + T cells ( 13 ).

Article Title: Compositions and methods for tumour therapy
Article Snippet: One method of using the vectors, provided by this invention, is to prepare a cellular immunogen such as a vaccine from tumour cells derived from one or more individuals by treating such tumour cells with a vector for downregulating osteonectin, and to administer this as an immunogen or vaccine for treatment of other subjects, e.g. patients.

Plasmid Preparation:

Article Title: SEMA4D antibody, preparation method therefor and use thereof
Article Snippet: C. DNA Immunogen: The nucleotide sequence containing the sequence encoding the full length of human SEMA4D (as shown in SEQ ID No: 422 in sequence listing, as shown in the cellular immunogen) was cloned into the pCP vector, and the plasmid pCP-hSEMA4D was prepared according to the above method. (II) Preparation of Hybridoma Cells and Screening of Antibody A.

Article Title: TRAIL Deficiency Does Not Rescue Impaired CD8 + T Cell Memory Generated in the Absence of CD4 + T Cell Help
Article Snippet: Using a cellular immunogen requiring cross-priming or lymphocytic choriomeningitis virus (LCMV) infection, it was demonstrated that mRNA for TRAIL was selectively up-regulated in unhelped CD8 + T cells following in vitro restimulation and that TRAIL blockade rescued the expansion of restimulated CD8 + T cells ( 13 ).

Article Title: Compositions and methods for tumour therapy
Article Snippet: One method of using the vectors, provided by this invention, is to prepare a cellular immunogen such as a vaccine from tumour cells derived from one or more individuals by treating such tumour cells with a vector for downregulating osteonectin, and to administer this as an immunogen or vaccine for treatment of other subjects, e.g. patients.

Cloning:

Article Title: SEMA4D antibody, preparation method therefor and use thereof
Article Snippet: C. DNA Immunogen: The nucleotide sequence containing the sequence encoding the full length of human SEMA4D (as shown in SEQ ID No: 422 in sequence listing, as shown in the cellular immunogen) was cloned into the pCP vector, and the plasmid pCP-hSEMA4D was prepared according to the above method. (II) Preparation of Hybridoma Cells and Screening of Antibody A.

Article Title: TRAIL Deficiency Does Not Rescue Impaired CD8 + T Cell Memory Generated in the Absence of CD4 + T Cell Help
Article Snippet: Using a cellular immunogen requiring cross-priming or lymphocytic choriomeningitis virus (LCMV) infection, it was demonstrated that mRNA for TRAIL was selectively up-regulated in unhelped CD8 + T cells following in vitro restimulation and that TRAIL blockade rescued the expansion of restimulated CD8 + T cells ( 13 ).

Article Title: Compositions and methods for tumour therapy
Article Snippet: One method of using the vectors, provided by this invention, is to prepare a cellular immunogen such as a vaccine from tumour cells derived from one or more individuals by treating such tumour cells with a vector for downregulating osteonectin, and to administer this as an immunogen or vaccine for treatment of other subjects, e.g. patients.

Virus:

Article Title: SEMA4D antibody, preparation method therefor and use thereof
Article Snippet: C. DNA Immunogen: The nucleotide sequence containing the sequence encoding the full length of human SEMA4D (as shown in SEQ ID No: 422 in sequence listing, as shown in the cellular immunogen) was cloned into the pCP vector, and the plasmid pCP-hSEMA4D was prepared according to the above method. (II) Preparation of Hybridoma Cells and Screening of Antibody A.

Article Title: TRAIL Deficiency Does Not Rescue Impaired CD8 + T Cell Memory Generated in the Absence of CD4 + T Cell Help
Article Snippet: Using a cellular immunogen requiring cross-priming or lymphocytic choriomeningitis virus (LCMV) infection, it was demonstrated that mRNA for TRAIL was selectively up-regulated in unhelped CD8 + T cells following in vitro restimulation and that TRAIL blockade rescued the expansion of restimulated CD8 + T cells ( 13 ).

Article Title: Compositions and methods for tumour therapy
Article Snippet: One method of using the vectors, provided by this invention, is to prepare a cellular immunogen such as a vaccine from tumour cells derived from one or more individuals by treating such tumour cells with a vector for downregulating osteonectin, and to administer this as an immunogen or vaccine for treatment of other subjects, e.g. patients.

Infection:

Article Title: SEMA4D antibody, preparation method therefor and use thereof
Article Snippet: C. DNA Immunogen: The nucleotide sequence containing the sequence encoding the full length of human SEMA4D (as shown in SEQ ID No: 422 in sequence listing, as shown in the cellular immunogen) was cloned into the pCP vector, and the plasmid pCP-hSEMA4D was prepared according to the above method. (II) Preparation of Hybridoma Cells and Screening of Antibody A.

Article Title: TRAIL Deficiency Does Not Rescue Impaired CD8 + T Cell Memory Generated in the Absence of CD4 + T Cell Help
Article Snippet: Using a cellular immunogen requiring cross-priming or lymphocytic choriomeningitis virus (LCMV) infection, it was demonstrated that mRNA for TRAIL was selectively up-regulated in unhelped CD8 + T cells following in vitro restimulation and that TRAIL blockade rescued the expansion of restimulated CD8 + T cells ( 13 ).

Article Title: Compositions and methods for tumour therapy
Article Snippet: One method of using the vectors, provided by this invention, is to prepare a cellular immunogen such as a vaccine from tumour cells derived from one or more individuals by treating such tumour cells with a vector for downregulating osteonectin, and to administer this as an immunogen or vaccine for treatment of other subjects, e.g. patients.

In Vitro:

Article Title: SEMA4D antibody, preparation method therefor and use thereof
Article Snippet: C. DNA Immunogen: The nucleotide sequence containing the sequence encoding the full length of human SEMA4D (as shown in SEQ ID No: 422 in sequence listing, as shown in the cellular immunogen) was cloned into the pCP vector, and the plasmid pCP-hSEMA4D was prepared according to the above method. (II) Preparation of Hybridoma Cells and Screening of Antibody A.

Article Title: TRAIL Deficiency Does Not Rescue Impaired CD8 + T Cell Memory Generated in the Absence of CD4 + T Cell Help
Article Snippet: Using a cellular immunogen requiring cross-priming or lymphocytic choriomeningitis virus (LCMV) infection, it was demonstrated that mRNA for TRAIL was selectively up-regulated in unhelped CD8 + T cells following in vitro restimulation and that TRAIL blockade rescued the expansion of restimulated CD8 + T cells ( 13 ).

Article Title: Compositions and methods for tumour therapy
Article Snippet: One method of using the vectors, provided by this invention, is to prepare a cellular immunogen such as a vaccine from tumour cells derived from one or more individuals by treating such tumour cells with a vector for downregulating osteonectin, and to administer this as an immunogen or vaccine for treatment of other subjects, e.g. patients.

Derivative Assay:

Article Title: SEMA4D antibody, preparation method therefor and use thereof
Article Snippet: C. DNA Immunogen: The nucleotide sequence containing the sequence encoding the full length of human SEMA4D (as shown in SEQ ID No: 422 in sequence listing, as shown in the cellular immunogen) was cloned into the pCP vector, and the plasmid pCP-hSEMA4D was prepared according to the above method. (II) Preparation of Hybridoma Cells and Screening of Antibody A.

Article Title: TRAIL Deficiency Does Not Rescue Impaired CD8 + T Cell Memory Generated in the Absence of CD4 + T Cell Help
Article Snippet: Using a cellular immunogen requiring cross-priming or lymphocytic choriomeningitis virus (LCMV) infection, it was demonstrated that mRNA for TRAIL was selectively up-regulated in unhelped CD8 + T cells following in vitro restimulation and that TRAIL blockade rescued the expansion of restimulated CD8 + T cells ( 13 ).

Article Title: Compositions and methods for tumour therapy
Article Snippet: One method of using the vectors, provided by this invention, is to prepare a cellular immunogen such as a vaccine from tumour cells derived from one or more individuals by treating such tumour cells with a vector for downregulating osteonectin, and to administer this as an immunogen or vaccine for treatment of other subjects, e.g. patients.



Similar Products

90
ImmunoGen Inc cellular immunogen
Cellular Immunogen, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular+immunogen/t+cell+immunogen/us12018078-388-36-31
Average 90 stars, based on 1 article reviews
cellular immunogen - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ImmunoGen Inc dna encoding the human fgfr3 extra cellular domain (ecd) protein (immunogen 2)
Dna Encoding The Human Fgfr3 Extra Cellular Domain (Ecd) Protein (Immunogen 2), supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular+immunogen/fgfr3+ecd+protein/us11505611-496-1-11
Average 90 stars, based on 1 article reviews
dna encoding the human fgfr3 extra cellular domain (ecd) protein (immunogen 2) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ImmunoGen Inc fgfr3 extra cellular domain (ecd) protein (immunogen 2)
Fgfr3 Extra Cellular Domain (Ecd) Protein (Immunogen 2), supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular+immunogen/fgfr3+ecd+protein/us11505611-497-0-6
Average 90 stars, based on 1 article reviews
fgfr3 extra cellular domain (ecd) protein (immunogen 2) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ImmunoGenes cellular immunogenes
Cellular Immunogenes, supplied by ImmunoGenes, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cellular+immunogen/cellular+immunogenes/pm09482184-121-18-19
Average 90 stars, based on 1 article reviews
cellular immunogenes - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results